Posted by Michael Wonder on 24 Oct 2019
Knight Therapeutics and SIFI announce approval of Netildex in Canada
23 October 2019 - Knight Therapeutics and SIFI today announced that Health Canada has approved Netildex for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical therapy to reduce the risk of bacterial infection is appropriate.
Knight and SIFI entered into an exclusive Canadian agreement Netildex in August 2016.
